Department of Error (DOI:10.1016/S0140-6736(06)69571-8);Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study

Lancet

Volumn 368, Issue 9548, 2006, Pages 1660-1672

  Scheen, André J ^a   Finer, Nick ^b   Hollander, Priscilla ^c   Jensen, Michael D ^d   Van Gaal, Luc F ^e  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c DALLAS DIABETES AND ENDOCRINE CENTER AT MEDICAL CITY   (United States)

^d MAYO CLINIC   (United States)

^e ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A; METFORMIN; PLACEBO; RIMONABANT; SULFONYLUREA;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONSERVATIVE TREATMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXERCISE; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; LONG TERM CARE; LOW CALORY DIET; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MOOD DISORDER; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; WEIGHT CHANGE; WEIGHT REDUCTION;

EID: 33751001942     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)69699-2     Document Type: Erratum

References (49)

1. Alexander C., Landsman P., Teutsch S., and Haffner S. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 52 (2003) 1210-1214
2. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
3. Haffner S., Lehto S., Ronnemaa T., Pyorala K., and Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339 (1998) 229-234
4. Booth G., Kapral M., Fung K., and Tu J. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet 368 (2006) 29-36
5. Scheen A. Current management strategies for coexisting diabetes mellitus and obesity. Drugs 63 (2003) 1165-1184
6. Yusuf S., Hawken S., Ôunpuu S., et al. Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: case-control study. Lancet 366 (2005) 1640-1649
7. Chan J., Rimm E., Colditz G., Stampfer M., and Willett W. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care 17 (1994) 961-969
8. Wing R., Marcus M., Epstein L., and Salata R. Type II diabetic subjects lose less weight than their overweight nondiabetic spouses. Diabetes Care 10 (1987) 563-566
9. Howlett A., Breivogel C., Childers S., Deadwyler S., Hampson R., and Porrino L. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 47 suppl 1 (2004) 345-358
10. Di Marzo V., Goparaju S., Wang L., et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410 (2001) 822-825
11. Ravinet Trillou C., Arnone M., Menet C., et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 284 (2003) R345-R353
12. Poirier B., Bidouard J., Cadrouvele C., et al. The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes Metab 7 (2005) 65-72
13. Bensaid M., Gary-Bobo M., Esclangon A., et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 63 (2003) 908-914
14. Osei-Hyiaman D., DePetrillo M., Pacher P., et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 115 (2005) 1298-1305
15. Liu Y., Connoley I., Wilson C., and Stock M. Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int J Obes Relat Metab Disord 29 (2005) 183-187
16. Matias I., Gonthier M., Orlando P., et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and β-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 91 (2006) 3171-3180
17. Van Gaal L., Rissanen A., Scheen A., Ziegler O., and Rössner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365 (2005) 1389-1397
18. Pi-Sunyer F., Aronne L., Heshmati H., Devin J., Rosenstock J., and RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. RIO-North America: a randomized controlled trial. JAMA 295 (2006) 761-775
19. Després J., Golay A., Sjöström L., and Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353 (2005) 2121-2134
20. Matthews D., Hosker J., Rudenski A., Naylor B., Treacher D., and Turner R. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
21. Ware J., and Sherbourne C. The MOS 36-item short-form health survey (SF-36). Med Care 30 (1992) 473-483
22. Kolotkin R., Crosby R., Kosloski K., and Williams G. Development of a brief measure to assess quality of life in obesity. Obes Res 9 (2001) 102-111
23. Kolotkin R., and Crosby R. Psychometric evaluation of the Impact Of Weight On Quality Of Life-Lite Questionnaire (IWQOL-Lite) in a community sample. Quality of Life Research 11 (2002) 157-171
24. Hill A., Rogers P., and Blundell J. Techniques for the experimental measurement of human being behaviour and food intake: a practical guide. Int J Obes Relat Metab Disord 19 (1995) 361-375
25. Zigmond A., and Snaith R. The hospital anxiety and depression scale. Acta Psychiatr Scand 67 (1983) 361-370
26. Hochberg Y. A sharper Bonferonni procedure for multiple tests of significance. Biometrika 75 (1988) 800-802
27. Gadbury G., Coffey C., and Allison D. Modern statistical methods for handling missing repeated measurements in obesity trial data: beyond LOCF. Obes Rev 4 (2003) 175-184
28. Wood A., White I., Hillsdon M., and Carpenter J. Comparison of imputation and modelling methods in the analysis of a physical activity trial with missing outcomes. Int J Epidemiol 34 (2005) 89-99
29. Buyse M., and Molenberghs G. Criteria for the validation of surrogate endpoints in randomized experiments. Biometrics 54 (1998) 1014-1029
30. International Diabetes Federation. Global guideline for type 2 diabetes. http://www.idf.org/home/index.cfm?node=1457 (accessed Oct 9, 2006)
31. American Diabetes Association. Clinical practice recommendations 2005. Diabetes Care 28 suppl 1 (2005) S1-S79
32. Klein S., Burke L., Bray G., et al. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation 110 (2004) 2952-2967
33. Stratton I., Adler A., Neil H., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321 (2000) 405-412
34. DeFronzo R., Ratner R., Han J., Kim D., Fineman M., and Baron A. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28 (2005) 1092-1100
35. Gaede P., Vedel P., Larsen N., Jensen G., Parving H., and Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348 (2003) 383-393
36. Stumvoll M., Goldstein B., and van Haeften T. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365 (2005) 1333-1346
37. Eckel R., Grundy S., and Zimmet P. The metabolic syndrome. Lancet 365 (2005) 1415-1428
38. Danesh J., Wheeler J., Hirschfield G., et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 350 (2004) 1387-1397
39. Cota D., Marsicano G., Tschop M., et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 112 (2003) 423-431
40. Chandran M., Phillips S., Ciaraldi T., and Henry R. Adiponectin: more than just another fat cell hormone?. Diabetes Care 26 (2003) 2442-2450
41. Sattar N., Wannamethee G., Sarwar N., et al. Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation 114 (2006) 623-629
42. Williamson D., Thompson T., Thun M., Flanders D., Pamuk E., and Byers T. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 23 (2000) 1499-1504
43. Guare J., Wing R., and Grant A. Comparison of obese NIDDM and nondiabetic women: short- and long-term weight loss. Obes Res 3 (1995) 329-335
44. Anon. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 (1998) 837-853
45. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 (2002) 393-403
46. Wing R., Koeske R., Epstein L., Nowalk M., Gooding W., and Becker D. Long-term effects of modest weight loss in type II diabetic patients. Arch Intern Med 147 (1987) 1749-1753
47. Nathan D., Buse J., Davidson M., et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29 (2006) 1963-1972
48. Norris S., Zhang X., Avenell A., et al. Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis. Arch Intern Med 164 (2004) 395-404
49. Padwal R., Li S., and Lau D. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obes Relat Metab Disord 27 (2003) 1437-1446